Novye vozmozhnosti ispol'zovaniya targetnoy terapii v lechenii nekotorykh solidnykh opukholey (po materialam ESMO-2014)
- Authors: Dobrova N.V1
-
Affiliations:
- Issue: No 17 (2014)
- Pages: 32-37
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287456
- ID: 287456
Cite item
Open Access
Access granted
Abstract
The article presents results of studies on the effectiveness of targeted therapy in breast cancer, melanoma, and thyroid cancer. Survival analysis in the CLEOPATRA study, efficacy and safety of bevacizumab in the IMELDA study, and results of double-blind randomized BRIM study and multicenter, double-blind, placebo-controlled SELECT study in patients with thyroid cancer are discussed in details.
Keywords
Full Text
References
- Abstract 350O_PR - Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).
- Abstract 352O - Efficacy and safety of maintenance bevacizumab (BEV) with or without capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mBC): IMELDA randomised phase III trial.
- Abstract 353O - Efficacy and safety in TANIA, a randomised phase III trial of continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative local-ly recurrent/metastatic breast cancer (LR/mBC).
- Abstract LBA5_PR - Phase 3, Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT0 1689519).
- Larkin J., Ascierto P.A., Dreno B., et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. NEJM 2014; published online September 29. doi: 10.1056/NEJ Moa 1408868.
- LBA4_PR - COMBI-v: A randomised, open-label, Phase III study comparing the combination of dabrafenib (D) and trametinib (T) та при метастатическом почечноклеточном раке показала хорошую переносимость и эффективность лечения. MPDL3280A продолжает изучаться при меланоме, колоректальном раке, раке почки, немелкоклеточном раке легкого При лечении немелкоклеточного рака легкого эффективность анти -PD-L-1 терапии корелировала с экспрессией PD-L-1 в иммунных клетках, инфильтрирующих опухоль (р=0,02), но не коррелировала с экспрессией рецепторов в опухолевых клетках [11]. to vemurafenib (V) as first-line therapy in patients (pts) with unresectable ormetastatic BRAF V600E/K mutation-positive cutaneous melanoma.
- P Subgroup analyses of a phase 3, multucenter, double-blind, placebo-controlled trail of lenvatinib (E7080) in patients with I131-refractory differentiated tireod cancer.
- Abstract: 808O - Inhibition of PD-L1 BY MPDL3280A leads to clinical activity in PTS with metastatic urothelial bladder cancer (UBC).
- Abstract: 1322P-Biomarkers associated with clinical activity of PD-L1 blockade In non-small cell lung cancer (NSCLC) patients (PTS) in a phase i study of MPDL3280A.
Supplementary files
